• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Akouos Inc. (Amendment)

    1/10/23 12:48:26 PM ET
    $AKUS
    Specialty Chemicals
    Consumer Discretionary
    Get the next $AKUS alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.3 AKOUOS INC COMMON STOCK Cusip #00973J101 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #00973J101 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 416,512 Item 6: 0 Item 7: 416,512 Item 8: 0 Item 9: 416,512 Item 11: 1.127% Item 12: HC Cusip #00973J101 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 416,512 Item 8: 0 Item 9: 416,512 Item 11: 1.127% Item 12: IN Item 1(a). Name of Issuer: AKOUOS INC Item 1(b). Address of Issuer's Principal Executive Offices: 645 Summer Street, Suite 200 Boston, MA 02210 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 00973J101 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 416,512 (b) Percent of Class: 1.127% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 416,512 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of AKOUOS INC. No one other person's interest in the COMMON STOCK of AKOUOS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing orinfluencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. January 9, 2023 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on January 9, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of AKOUOS INC at December 30, 2022. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.
    Get the next $AKUS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKUS

    DatePrice TargetRatingAnalyst
    9/29/2022$12.00Outperform
    William Blair
    More analyst ratings

    $AKUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Akouos with a new price target

      William Blair initiated coverage of Akouos with a rating of Outperform and set a new price target of $12.00

      9/29/22 9:08:33 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • HC Wainwright & Co. initiated coverage on Akouos with a new price target

      HC Wainwright & Co. initiated coverage of Akouos with a rating of Buy and set a new price target of $25.00

      4/27/21 6:28:58 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • Akouos downgraded by BofA Securities with a new price target

      BofA Securities downgraded Akouos from Buy to Neutral and set a new price target of $20.00 from $24.00 previously

      3/30/21 6:33:57 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary

    $AKUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Akouos Inc. (Amendment)

      SC 13G/A - Akouos, Inc. (0001722271) (Subject)

      2/14/23 3:32:27 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Akouos Inc. (Amendment)

      SC 13G/A - Akouos, Inc. (0001722271) (Subject)

      2/10/23 1:59:31 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Akouos Inc. (Amendment)

      SC 13G/A - Akouos, Inc. (0001722271) (Subject)

      1/10/23 12:48:26 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary

    $AKUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Walker Paul Edward (tax withholding)

      4 - Akouos, Inc. (0001722271) (Issuer)

      12/2/22 5:13:26 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Sonsini Peter W. (tax withholding)

      4 - Akouos, Inc. (0001722271) (Issuer)

      12/2/22 5:12:13 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Sandell Scott D to satisfy withholding tax

      4 - Akouos, Inc. (0001722271) (Issuer)

      12/2/22 5:10:58 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary

    $AKUS
    Financials

    Live finance-specific insights

    See more
    • Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights

      -Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial -Continued progress toward planned IND submission for AK-antiVEGF in 2023 -Announced on October 18 definitive agreement for Eli Lilly and Company to acquire Akouos BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the third quarter ended September 30, 2022 and provides business highlights. "This has been a transformative year for us, and we've achieved

      11/14/22 7:15:00 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • Akouos Reports Second Quarter 2022 Financial Results and Provides Business Highlights

      Submitted IND for AK-OTOF to FDA Continued progress toward planned IND submission for AK-antiVEGF Presented new nonclinical data at ASGCT supporting the proposed clinical development of AK-OTOF and highlighting strategies for regulated gene expression in the inner ear Received a notice of allowance from USPTO for claims covering compositions, including AK-OTOF, and methods of treatment useful for OTOF-mediated hearing lossEnded Q2 2022 with a strong cash position of $192.9 million BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing los

      8/15/22 7:00:00 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • Akouos Reports First Quarter 2022 Financial Results and Provides Business Highlights

      - Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Presenting new nonclinical data at ASGCT supporting the planned clinical development of AK-OTOF and highlighting the potential use of microRNA target sites in AAV vectors for regulated gene expression in the inner ear - Presented new nonclinical data at ARO demonstrating potential of precision genetic medicine platform to address a broad range of inner ear conditions -Ended the first quarter with a strong cash position of $209.1 million BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potenti

      5/12/22 7:45:00 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary

    $AKUS
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $AKUS
    SEC Filings

    See more
    • Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases

      INDIANAPOLIS, Dec. 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ:AKUS). The acquisition expands Lilly's efforts in genetic medicines to include Akouos's portfolio of potential first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss. "Akouos brings more top-tier talent and an important pipeline to Lilly's Institute for Genetic Medicine that will further accelerate our work to advance genetic medicines for people living with difficult-to-treat diseases," said Andrew C. Adams, Ph.D., senior vice president of genetic medicine

      12/1/22 8:41:00 AM ET
      $AKUS
      $LLY
      Specialty Chemicals
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly and Akouos Announce Expiration of Akouos Tender Offer

      INDIANAPOLIS and BOSTON, Nov. 30, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Akouos, Inc. (NASDAQ:AKUS) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Akouos's common stock in exchange for (a) $12.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones (the "Offer"), expire

      11/30/22 6:50:00 AM ET
      $AKUS
      $LLY
      Specialty Chemicals
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights

      -Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial -Continued progress toward planned IND submission for AK-antiVEGF in 2023 -Announced on October 18 definitive agreement for Eli Lilly and Company to acquire Akouos BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the third quarter ended September 30, 2022 and provides business highlights. "This has been a transformative year for us, and we've achieved

      11/14/22 7:15:00 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 15-12G filed by Akouos Inc.

      15-12G - Akouos, Inc. (0001722271) (Filer)

      12/12/22 4:11:07 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form EFFECT filed by Akouos Inc.

      EFFECT - Akouos, Inc. (0001722271) (Filer)

      12/6/22 12:15:08 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form POS AM filed by Akouos Inc.

      POS AM - Akouos, Inc. (0001722271) (Filer)

      12/1/22 4:42:00 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary

    $AKUS
    Leadership Updates

    Live Leadership Updates

    See more
    • Akouos Appoints Aaron Tward, M.D., Ph.D., as Chief Scientific Officer

      BOSTON, March 10, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Aaron Tward, M.D., Ph.D., as chief scientific officer. Dr. Tward is a surgeon and a scientist with deep experience in genetics, genomics, gene delivery, high-throughput sequencing technologies, and the clinical care of patients with conditions of the ear and skull base. Dr. Tward was previously a member of the Akouos scientific advisory board since 2018. As chief scientific officer, he will lead the research team, and provide strategic scie

      3/10/22 7:00:00 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • Akouos Appoints Stacy Price as Chief Technical Officer

      BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Stacy Price as chief technical officer. Ms. Price brings to Akouos more than 25 years of experience managing clinical and commercial biotechnology manufacturing and technical operations for a wide range of therapeutic modalities, including gene therapy. At Akouos, she will be responsible for the strategy and operations of vector development and manufacturing, as well as device development and engineering. "We are excited to welcome Stacy to

      11/1/21 7:00:00 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • Akouos Appoints Dr. Kathy Reape as Chief Development Officer

      BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Dr. Kathy Reape as chief development officer. Dr. Reape brings over 20 years of experience in the pharmaceutical industry, including significant gene therapy translational and development expertise, to Akouos. "We welcome Dr. Reape to the Akouos team at this exciting time in the company's growth, as we continue to advance the AK-OTOF and AK-antiVEGF programs towards our planned IND submissions in 2022," said Manny Simons, Ph.D., M.B.A., co-f

      5/7/21 7:00:00 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary